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A B S T R A C T
Purpose
To evaluate randomly the role of hyperfractionated cyclophosphamide (hyper-C) dose intensiﬁcation
in adults with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic leukemia
treated with a pediatric-inspired protocol and to determine the upper age limit for treatment tol-
erability in this context.
Patients and Methods
A total of 787 evaluable patients (B/T lineage, 525 and 262, respectively; median age, 36.1 years)
were randomly assigned to receive a standard dose of cyclophosphamide or hyper-C during ﬁrst
induction and late intensiﬁcation. Compliance with chemotherapy was assessed by median doses
actually received during each treatment phase by patients potentially exposed to the full planned
doses.
Results
Overall complete remission (CR) rate was 91.9%. With a median follow-up of 5.2 years, the 5-year
rate of event-free survival (EFS) and overall survival (OS) was 52.2% (95% CI, 48.5% to 55.7%) and
58.5% (95% CI, 54.8% to 61.9%), respectively. Randomization to the hyper-C arm did not increase
the CR rate or prolong EFS or OS. As a result of worse treatment tolerance, advanced age con-
tinuously affected CR rate, EFS, and OS, with 55 years as the best age cutoff. At 5 years, EFS was
55.7% (95% CI, 51.8% to 59.4%) for patients younger than 55 years of age versus 25.8% (95% CI,
19.9% to 35.6%) in older patients (hazard ratio, 2.16; P, .001). Patients$ 55 years of age, in whom
a lower compliance to the whole planned chemotherapy was observed, beneﬁted signiﬁcantly from
hyper-C, whereas younger patients did not.
Conclusion
No signiﬁcant beneﬁt was associated with the introduction of a hyper-C sequence into a frontline
pediatric-like adult acute lymphoblastic leukemia therapy. Overall, tolerability of an intensive
pediatric-derived treatment was poor in patients $ 55 years of age.
J Clin Oncol 36:2514-2523. © 2018 by American Society of Clinical Oncology
INTRODUCTION
The treatment of adult Philadelphia chromo-
some (Ph)–negative acute lymphoblastic leukemia
(ALL) has recently evolved. New insights into ALL
genetics have contributed to a better compre-
hension and prognostic stratiﬁcation of the dis-
ease.1 In addition, despite the lack of major new
drugs until recently, important therapeutic im-
provements have occurred. After several reports
showing a better outcome of adolescents treated
with pediatric rather than adult protocols, in-
tensiﬁed pediatric-inspired regimens with con-
tinuous dose-intense exposure to chemotherapy
and higher cumulative doses of nonmyelotoxic
drugs such as L-asparaginase and glucocorticoids
have been proposed for adult patients.2 The
Group of Research on Adult ALL (GRAALL)
Intergroup contributed to the validation of the
feasibility and superiority of such an intensiﬁed
approach in its ﬁrst GRAALL-2003 trial, which
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demonstrated signiﬁcant increases in complete remission (CR)
rate, event-free survival (EFS), and overall survival (OS) compared
with a conventional historical protocol.3 The present GRAALL-
2005 trial aimed to conﬁrm these results on a larger scale and
included a randomized evaluation of sequential administration of
hyperfractionated cyclophosphamide (hyper-C), a cornerstone of
the adult hyperfractionated cyclophosphamide, vincristine, doxo-
rubicin, and dexamethasone (hyper-CVAD) regimen.4 Another
important issue studied was the role of age on outcome to deﬁne
more precisely the population of adults likely to beneﬁt from
a pediatric-like approach, an issue that remains controversial.
PATIENTS AND METHODS
Study Design
The multicenter GRAALL-2005 protocol was relatively similar to that
of GRAALL-2003 but with the addition of two randomized evaluations:
a hyper-C sequence during induction and late intensiﬁcation in all patients
and rituximab in the subset of patients with CD20+ B-cell precursor (BCP)
ALL. The whole study design assumed that no interaction would be
observed between these two evaluations, as actually reported in the
GRAALL-2005/R substudy that showed a signiﬁcant beneﬁt in EFS for
patients who received rituximab.5
Study Population
Patients 18 to 59 years of age with newly diagnosed Ph-negative BCP-
or T-lineage ALLwere eligible in the absence of other evolving malignancy,
pregnancy, HIV infection or active viral hepatitis, or organ damage that
contraindicated intensive chemotherapy. Patients with Burkitt mature
B-cell lymphoma/leukemia or lymphoblastic lymphoma were not eligible.
Between May 2006 and April 2014, 813 patients were randomly assigned.
Eleven patients had noneligibility criteria (seven with Ph-positive ALL, one
with lymphoblastic lymphoma, one with acute myeloid leukemia, one with
concomitant malignancy, and one with HIV infection), 12 received a dif-
ferent therapy from the beginning for various reasons, and three withdrew
consent. These 26 patients were excluded from the primary intention-to-
treat analysis presented here, which thus included 787 patients (Fig 1).
Study Overview
The trial was conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines and approved by the Institutional
Ethics Committee of Ile-de-France VI. Signed informed consent was ob-
tained from all patients at trial entry. The GRAALL scientiﬁc board designed
the study. The GRAALL investigators and their research teams collected data.
A list of centers and investigators is provided in the Data Supplement.
Treatments
The full GRAALL-2005 protocol is detailed in the Data Supplement.
Treatment phases comprised a prephase, a ﬁrst induction, an optional
second induction if no CR after the ﬁrst induction, consolidation 1,
consolidation 2, late intensiﬁcation, consolidation 3, prophylactic CNS
irradiation, and 2-year maintenance. During the ﬁrst induction phase,
cyclophosphamide was given at the standard dosage of 750mg/m2 on day 1
for all groups. According to the randomization arm, cyclophosphamide
was then given at the same 750 mg/m2 standard dose on day 15, which was
termed standard-C group, or at the intensiﬁed dose of 300 mg/m2 every
12 hours on days 15, 16, and 17 (six total infusions), which was termed
hyper-C group. For patients who had reached CR after the ﬁrst induction,
standard-C or hyper-C also was used during the late intensiﬁcation phase
according to randomization arm. No chemotherapy dose adaptations were
planned according to patients’ age.
Risk Groups and Allogeneic Hematopoietic Stem-Cell
Transplantation
High-risk ALLwas deﬁned by at least one of the following criteria: CNS
involvement; low hypodiploidy/near triploidy as previously described6;
complex karyotype6,7; poor early peripheral blood blast clearance, deﬁned by
a peripheral blood blast count. 1.03 109/L at the end of the prephase; poor
early bone marrow (BM) blast clearance, deﬁned by. 5% blasts in the BM
at day 8 of ﬁrst induction; and late CR, deﬁned by the need for a second
induction course to reach CR. Additional factors were used in patients with
BCP-ALL, including WBC $ 30 3 109/L; immature CD10– immuno-
phenotype; KMT2A gene rearrangement, deﬁned as t(4;11) chromosomal
translocation and/or KMT2A-AFF1 gene fusion, or another KMT2A rear-
rangement; and t(1;19) chromosomal translocation and/or TCF3-PBX1 gene
fusion. Patients who did not present with any criteriawere classiﬁed as having
standard-risk ALL. Molecular minimal residual disease (MRD) monitoring
was neither mandatory nor used as a treatment-stratifying factor. MRD levels
were evaluated on immunoglobulin/T-cell receptor gene rearrangements on
BM samples from a subset of 339 patients as previously described.8 Al-
logeneic hematopoietic stem-cell transplantation (HSCT) was indicated in
the ﬁrst CR for all patients# 55 years of age with high- or undetermined-
risk ALL and a matched related or 10/10 allelic-matched unrelated donor.9
Statistical Methods
The primary study end point was EFS. A sample size of 810 patients
was estimated to be required to detect a 10% gain in 5-year EFS from 35% in
the standard-C to 45% in the hyper-C arm (hazard ratio [HR], 0.76; two-
sided log-rank test power, 85%; type I error, 5%). Analyses were performed
according to the intention-to-treat principle. OS and EFS were calculated
from the date of randomization. Events that accounted for EFS were failure
of CR induction, relapse, and death. Secondary end points were OS, cu-
mulative incidence of relapse (CIR), cumulative incidence of death in ﬁrst
remission (CID), and safety. Failure time data, except for cumulative in-
cidences, were estimated by Kaplan-Meier method10 then compared by log-
rank test, with HRs estimated by the Cox proportional hazards regression
model.11 Proportional hazards assumptions were graphically checked. For
estimating CIR and CID, deaths in ﬁrst remission and relapses were taken
into account as competing risks using cumulative incidence curves. For CIR
and CID comparisons, Cox proportional hazards regression models were
used to estimate cause-speciﬁc HR (SHR). Because most patients who
received allogeneic HSCT did not eventually receive the second hyper-C
sequence, we also performed sensitivity analyses after censoring those who
underwent transplantation during ﬁrst CR at the time of HSCT. Medians
with interquartile ranges were compared using theMann-WhitneyU test. All
analyses were performedwith SAS 9.3 (SAS Institute, Cary, NC) or R version
2.14.0 (R packages survival, cmprsk; www.r-project.org) statistical software.
RESULTS
Patients
Patient characteristics are listed in Table 1. The median age
was 36.1 years. No imbalances existed between both randomization
groups except for a larger number of patients with BCP-ALL with
poor early BM blast clearance in the standard-C group. A patient
ﬂowchart is shown in Figure 1.
Hyper-C Versus Standard-C Randomization
A total of 723 patients (91.9%) achieved CR. The CR rate was
not signiﬁcantly higher in the hyper-C than in the standard-C arm
(93.6% v 90.2%; P = .091; Table 1). More patients, however,
achieved CR in one course in the hyper-C arm (P = .048). In
patients who achieved CR after the ﬁrst induction, the proportion
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of patients with a postinduction MRD level , 1024 was similar in
both arms (108 of 164 and 105 of 175 evaluable patients in the
standard-C and hyper-C arms, respectively; P = .31). Incidences of
induction death and resistant disease after induction were similar
in both arms, as was day 60 mortality (Table 1).
With a median follow-up of 5.25 years, 216 of 723 patients
with CR experienced relapse (relapse sites: 163 BM, 18 BM + CNS,
19 isolated CNS, ﬁve BM + other extramedullary sites, 11 isolated
other extramedullary sites). Overall, 322 patients died, including 90
deaths in ﬁrst CR (causes of death: 20 infections, 50 transplant-
related deaths, six secondary neoplasms, four fatal bleedings, two
myocardial infarctions, two suicides, and six unknown). Globally,
EFS and OS rates were estimated at 52.2% (95% CI, 48.5% to
55.7%) and 58.5% (95% CI, 54.8% to 61.9%), respectively, at
GRAALL-2005
Randomly assigned patients
(N = 813, including 220 patients randomly assigned
in the rituximab 2005/R substudy)
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(n = 10)
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(n = 1)
(n = 1)
(n = 60)
(n = 1)
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(n = 1)
(n = 4)
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(n = 1)
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(n = 3)
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(n = 12)
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Fig 1. CONSORT diagram. ALL, acute lymphoblastic leukemia; CR, complete remission; CR1, ﬁrst complete remission; HSCT, hematopoietic stem-cell transplantation;
hyper-C, hyperfractionated cyclophosphamide; standard-C, standard cyclophosphamide.
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5 years. As depicted in Figure 2A, EFS was not longer in the hyper-C
than in the standard-C arm (54.2% [95% CI, 49.0% to 59.2%] v
50.1% [95%CI, 44.9% to 55.1%] at 5 years; HR, 0.89; 95%CI, 0.72
to 1.09; P = .25). Similarly, OS (HR, 0.92; 95% CI, 0.74 to 1.14;
P = .45), CIR (SHR, 0.94; 95% CI, 0.72 to 1.22]; P = .62), and CID
(SHR, 1.04; 95%CI, 0.82 to 1.33; P = .63) were not longer or higher
in the hyper-C arm (Table 1). Similar results were observed when
the 278 patients who received HSCT in ﬁrst CR (259 of 513 eligible
patients + 19 patients with standard-risk ALL) were censored at the
time of HSCT (Data Supplement).
To investigate further the effects of hyper-C, we evaluated
treatment arm effects among various patient subgroups. Results
of this post hoc analysis (Fig 3) revealed a lower HR for EFS in favor
of the hyper-C arm in patients$ 55 years of age (HR, 0.51; 95%CI,
0.32 to 0.84), with a signiﬁcant interaction test (P = .029). No
interaction with rituximab administration was found in the 209
patients also randomly assigned in the GRAALL-2005/R study.
Effect of Age
Given this unexpected interaction between age and the efﬁcacy
of hyper-C, we analyzed the overall effect of increasing age on
outcome and compliance to the planned therapy. Table 2 lists patient
outcomes according to the ﬁve age subsets listed in Table 1. As
indicated, increasing age continuously worsened EFS and OS, with
55 years appearing to be the most relevant age cutoff. At younger
than 55 years of age, 5-year EFS and OS rates remained . 50%
(55.7% [95% CI, 51.8% to 59.4%] and 62.7% [95% CI, 58.8% to
66.3%], respectively), whereas in older patients, 5-year EFS and OS
rates were estimated at 25.8% (95% CI, 19.9% to 35.6%) and 27.4%
(95% CI, 18.3% to 37.4%) only (Fig 2B for EFS; Data Supplement
for OS). As listed in Table 2, this worse outcome was associated with
higher incidences of induction death and death in ﬁrst CR, even in
patients without transplants, rather than with higher incidences of
relapsed/refractory disease. Analysis of compliance to the planned
protocol revealed that patients$ 55 years of age received signiﬁcantly
lower doses of most chemotherapy drugs than younger patients
during each treatment phase (Table 3).
Figure 2C illustrates this interaction between age $ 55 years
and the hyper-C effect. A similar interaction was found when
patients who received HSCT in ﬁrst CR were censored at the time
of HSCT (Data Supplement). Despite that they retained lower EFS
than younger patients, patients $ 55 years of age signiﬁcantly
beneﬁted from the hyper-C regimen, whereas younger patients did
not. Of note, this beneﬁt was only observed in the subset of patients
with chemotherapy-sensitive ALL, deﬁned as good early BM blast
Table 1. Patient Characteristics and Outcomes According to Randomization Arm
Characteristic
Patients, No. (%)
PAll Standard-C Arm Hyper-C Arm
No. of patients 787 398 389
Median age, years (IQR) 36.1 (24.8-48.4) 36.4 (24.3-47.6) 35.7 (25.3-49.3) —
Age, years
18-24 200 (25.4) 106 (26.6) 94 (24.2) —
25-34 172 (21.9) 82 (20.6) 90 (23.1) —
35-44 171 (21.7) 94 (23.6) 77 (19.8) —
45-54 151 (19.2) 73 (18.4) 78 (20.1) —
$ 55 93 (11.8) 43 (10.8) 50 (12.8) —
BCP-ALL 525 (67) 266 (67) 259 (67) —
WBC $ 30 3 109/L 118 (22.5) 51 (19.2) 67 (25.9) —
CNS involvement 27 (5.1) 15 (5.6) 12 (4.6) —
t(4;11)/KMT2A-AFF1, No. evaluable 55 of 508 (10.8) 21 of 260 (8.1) 34 of 248 (13.7) —
t(9;11)/TCF3-PBX1, No. evaluable 21 of 486 (4.3) 9 of 252 (3.6) 12 of 234 (5.1) —
Poor early PB blast clearance, No. evaluable 79 of 523 (15.1) 42 of 266 (15.8) 37 of 257 (14.4) —
Poor early BM blast clearance, No. evaluable 189 of 515 (36.7) 111 of 261 (42.5) 78 of 254 (30.7) —
T-ALL 262 (33) 132 (33) 130 (33) —
CNS involvement 28 (10.7) 15 (11.4) 13 (10.0) —
Poor early PB blast clearance 104 of 262 (39.7) 57 of 132 (43.2) 47 of 130 (36.1) —
Poor early BM blast clearance 118 of 260 (45.4) 67 of 130 (51.5) 51 of 130 (39.2) —
High-risk ALL, No. evaluable 467 of 677 (69) 244 of 338 (72) 223 of 339 (66) —
Outcome
CR 723 (91.9) 359 (90.2) 364 (93.6) .09
CR in one course 705 (89.6) 348 (87.5) 357 (91.8) .05
Induction death 44 (5.6) 26 (6.5) 18 (4.6) .28
Resistant disease 20 (2.5) 13 (3.3) 7 (1.8) .26
60-day mortality 52 (6.6) 31 (7.8) 21 (5.4) .20
Allogeneic HSCT in ﬁrst CR 278 (35) 145 (36) 133 (34) .55
Time from CR to HSCT in ﬁrst CR, days (IQR) 111 (84-142) 112 (86-143) 110 (84-139) .69
5-year CIR, % (95% CI) 30.5 (27.2 to 34.1) 31.6 (26.9 to 36.8) 29.4 (25.0 to 34.5) .62
5-year CID, % (95% CI) 12.3 (10.1 to 15.0) 12.3 (9.2 to 16.2) 12.4 (9.3 to 16.4) .63
5-year EFS, % (95% CI) 52.2 (48.5 to 55.7) 50.1 (44.9 to 55.1) 54.2 (49.0 to 59.2) .25
5-year OS, % (95% CI) 58.5 (54.8 to 61.9) 57.4 (52.2 to 62.3) 59.5 (54.2 to 64.3) .45
Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; BM, bone marrow; CID, cumulative incidence of death in ﬁrst complete remission; CIR,
cumulative incidence of relapse; CR, complete remission; EFS, event-free survival; HSCT, hematopoietic stem-cell transplantation; hyper-C, hyperfractionated cy-
clophosphamide; IQR, interquartile range; OS, overall survival; PB, peripheral blood; standard-C, standard cyclophosphamide.
jco.org © 2018 by American Society of Clinical Oncology 2517
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clearance at day 8 (Data Supplement). Conversely, patients younger
than age 55 years drew no beneﬁt from the hyper-C treatment,
whatever their BM blast clearance was at day 8.
DISCUSSION
We report the results of the GRAALL-2005 trial, which enrolled
a large cohort of 787 adults age18 to 59 years with Ph-negative ALL.
These results are very close to those observed in an updated
analysis of our previous GRAALL-2003 study.3 In these two
consecutive trials, rates of CR were 93.5% and 91.9%; 5-year EFS,
53.0% and 52.2% (Data Supplement); and 5-year OS, 58.6% and
58.5%, respectively. Such achievements compare favorably to
previous adult-type protocols. For instance, in 1,418 adults with
Ph-negative ALL enrolled in the largest Medical Research Council
UKALL XII/ECOG E2993 trial, the OS rate was estimated at 43%
at 5 years.12,13
Better outcomes have been reported repeatedly when using
intensiﬁed protocols in younger adults, with 5-year OS rate esti-
mates approaching or even surpassing 60%. The ﬁrst trials to use
unmodiﬁed pediatric protocols included relatively low numbers of
patients and often were limited to selected adolescents and young
adults (AYAs) younger than 40 years of age.2 The largest C10403
trial from the US Intergroup evaluated the pediatric Children’s
Oncology Group regimen in AYAs 16 to 39 years of age.14 With
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Fig 2. Event-free survival (EFS). (A) EFS according to hyperfractionated cyclophosphamide (hyper-C) versus standard cyclophosphamide (standard-C) randomization. EFS
was not signiﬁcantly higher in the hyper-C arm than in the standard-C arm (hazard ratio [HR], 0.89; 95% CI, 0.72 to 1.09; P = .25). Five-year EFS estimates are listed in Table 1.
(B) EFS according to age subsets. Five-year EFS estimates are listed in Table 2. Patients$ 55 years of age had signiﬁcantly shorter EFS than those younger than 55 years
(HR, 2.16; 95%CI, 1.66 to 2.82; P, .001); at 5 years, EFS rate estimateswere 25.8% (95%CI, 16.9% to 35.6%) and 55.7% (95%CI, 51.8% to 59.4%), respectively.Within
the latter group, patients age 35 to 54 years had a shorter EFS than those age 18 to 34 years (HR, 1.31; 95% CI, 1.05 to 1.64; P = .019); at 5 years, EFS rate estimates were
52.2% (95% CI, 46.5% to 57.7%) and 58.7% (95% CI, 53.4% to 63.6%), respectively. (C) EFS according to age (, 55 or $ 55 years) and hyper-C versus standard-C
randomization. In the 18 to 54 age range, 5-year EFS rate estimates were 56.5% (95% CI, 51.0% to 61.7%) in the hyper-C versus 54.8% (95% CI, 49.3% to 60.0%) in the
standard-C arm (HR, 0.95; 95% CI, 0.76 to 1.19; P = .66). In patients $ 55 years of age, 5-year EFS rate estimates were 38.0% (95% CI, 23.8% to 52.1%) in the hyper-C
versus 12.0% (95%CI, 4.1% to 24.3%) in the standard-C arm (HR, 0.51; 95%CI, 0.32 to 0.84]; P= .007).With respect to each type of EFS event in this older age subset, the
complete remission rate was 82.0% versus 76.7% (P = .61), induction mortality was 18.0% versus 18.6% (P = .99), 5-year cumulative incidence of relapse was 33.3%
(95%CI, 20.8% to 50.5%) versus 45.8% (95%CI, 30.6% to 64.2%; HR, 0.66; 95%CI, 0.31 to 1.38; P= .27), and 5-year cumulative incidence of death in ﬁrst remissionwas
18.9% (95% CI, 9.4% to 35.8%) versus 36.9% (95% CI, 22.9% to 55.9%; HR, 0.48; 95% CI, 0.20 to 1.18; P = .11) in the hyper-C versus the standard-C arm, respectively.
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a relatively short median follow-up of 28 months, EFS and OS rates
were estimated at 66% (95% CI, 60% to 72%) and 78% (95% CI,
72% to 83%), respectively, at 2 years.14 Conversely, some European
study groups, including the Northern Italy Leukemia Group,15 the
German Multicenter Study Group for Adult ALL,16,17 and the
GRAALL, have developed pediatric-inspired protocols adapted to
be tolerated by adults up to 55 to 65 years of age. These groups
progressively and cautiously have incorporated most pediatric
treatment elements, even if allogeneic HSCTwas still proposed for
a majority of patients deﬁned by high-risk features or un-
satisfactory MRD response. Of note, early MRD response was not
used to stratify therapy in the GRAALL-2005 trial. Because the
predictive value of MRD for allogeneic HSCT superiority over
chemotherapy was later demonstrated,8,9 MRD levels currently are
used to guide additional therapy in the ongoing GRAALL-2014
study. To date, no randomized study has prospectively com-
pared an unmodiﬁed pediatric with a pediatric-derived protocol
in younger adults. Thus, no upper age limit has been recom-
mended for using a pediatric protocol in AYAs. Nevertheless, with
an estimated 2-year EFS rate of 65.1% (95% CI, 60.5% to 69.3%)
and 2-year OS rate of 74.3% (95% CI, 70.0% to 78.1%), the
outcome of the 456 patients# 39 years of age treated in the current
GRAALL-2005 trial seem to be very close to those observed with
the pediatric Children’s Oncology Group regimen in the C10403
trial.
The GRAALL-2005 trial enrolled patients up to 59 years of
age, whereas the upper age limit was 65 years in the Northern Italy
Leukemia Group ALL 09/00 study and remains at 55 years in the
German Multicenter Study Group for Adult ALL studies,15-17
which underscores a similar uncertainty with respect to the up-
per limit for using a pediatric-derived protocol in adults. This issue
was addressed retrospectively in the current report. Of note, in-
creasing age was already an unfavorable prognostic factor in the
previous GRAALL-2003 trial, with a best prognostic cutoff at
45 years at that time.3 In the current trial, this best cutoff increased
to 55 years, which might be due to statistical issues related to
different sample sizes but might also suggest that a learning phase
has been necessary to allow physicians to administer an intensiﬁed
protocol appropriately to adult patients. For instance, in patients
45 to 54 years of age, the CR rate increased from 86.0% to 89.4%
and the 5-year OS rate from 46.2% (95% CI, 30.8% to 60.2%) to
56.7% (95% CI, 48.0% to 64.5%) between the GRAALL-2003 and
GRAALL-2005 trials.
The poorer results obtained in older patients mostly were
related to worse tolerance of the planned therapy, with higher
treatment-related mortality, rather than to a higher incidence of
chemotherapy-resistant, refractory, or relapsed ALL. The poor
tolerability of pediatric-like ALL therapy is an important concern
in patients $ 55 years of age, with an induction death rate of
18.5%, a 25.5% incidence of death in ﬁrst CR in patients without
transplants, and a worse compliance with planned chemotherapy
doses. Even if it was planned to treat patients up to 59 years of age,
the GRAALL protocol cannot be administered easily to patients
age$ 55 years. Poor tolerance to L-asparaginase has been reported
in patients older than 50 years, with major hepatic, pancreatic,
metabolic, and thromboembolic toxicities.18-23 Such patients also
present a poorer tolerance to glucocorticoid therapy, which ex-
poses them to metabolic, vascular, and infectious complications. In
the GRAALL experience, the median age of patients who developed
invasive fungal infections before HSCT was 47 years.24 This poor
treatment tolerance, which led to a dismal 27.4% 5-year OS in the
older age population, suggests that 55 years is a reasonable upper
age limit to treat adult patients with ALL with a pediatric-derived
protocol. One might argue that an age limit is arbitrary and does
not reﬂect the real health status of patients. However, because
eligibility also speciﬁed a lack of organ dysfunction, the trial
population likely was more homogeneous than a general pop-
ulation of the same age, and age, nevertheless, retained its prog-
nostic value in patients selected for the trial.
Another important protocol used to treat adults with ALL is
the hyper-CVAD regimen. The concept of hyper-C was ﬁrst de-
veloped in childhood Burkitt mature B-cell lymphoma/leukemia,
which relies on the speciﬁc kinetics of this tumor,25 and was then
widely applied to adults and other lymphoid malignancies, in-
cluding BCP- and T-ALL. In 229 adults 15 to 59 years of age,
including patients with Ph-positive ALL, the CR rate was 94.8%
and estimated 5-year OS rate 51% in patients younger than 40 years
versus 30% in those age 40 to 59 years.4 With necessary caution
in interpreting results of single-center nonrandomized studies,
the hyper-CVAD regimen has been shown to be as effective as
Subgroup n HR (95% CI)
Age range
200 0.94 (0.60 to 1.46)
0.68 (0.43 to 1.09)
0.88 (0.56 to 1.37)
1.43 (0.90 to 2.27)
0.51 (0.32 to 0.84)
0.87 (0.61 to 1.26)
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0.95 (0.71 to 1.27)
0.68 (0.42 to 1.10)
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0.93 (0.71 to 1.22)
0.93 (0.73 to 1.19)
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0.96 (0.72 to 1.27)
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0.89 (0.72 to 1.09)
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118
210
467
602
183
468
307
104
105
578
787
0.25
18-24 years
25-34 years
35-44 years
45-54 years
≥ 55 years
ALL lineage
T lineage
B lineage
WBC (BCP-ALL)
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GRAALL-2005/R randomization
Yes  0
No   1
Yes  0
No   1
No rituximab
Rituximab
Not randomized
Overall
High 1
0.50 1.0 2.0
Favors Hyper-C
4.0
Favors Standard-C
Fig 3. Effects of hyperfractionated cyclophosphamide (hyper-C) versus standard
cyclophosphamide (standard-C) randomization on event-free survival in patient
subgroups. ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; BM, bone
marrow; HR, hazard ratio; PB, peripheral blood.
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a pediatric-derived protocol.26 In the GRAALL-2005 study, the role
of this hyper-C component was evaluated during induction and
late intensiﬁcation. In the context of a totally different protocol,
hyper-C failed to prolong EFS overall. Nevertheless, post hoc
analyses suggested that hyper-Cmight beneﬁt the group of patients
with ALL $ 55 years of age with good early sensitivity to che-
motherapy (ie, good early BM blast clearance before standard-C v
hyper-C initiation). Even if possibly a result of chance with respect
to the number of unplanned subgroup analyses, this observation
suggests that older patients who cannot optimally tolerate the
planned GRAALL protocol might beneﬁt from early intensiﬁcation
of a tolerable drug, at least if they do not have chemotherapy-
resistant ALL. Novel, more immediately tolerable strategies thus
could be designed for older patients as has been proposed with the
antibody drug conjugate inotuzumab ozogamicin.27
In conclusion, the results of the GRAALL-2005 study conﬁrm
the value of a pediatric-derived approach to treating adults with
Ph-negative ALL, at least those between 18 and 54 years of age,
because treatment compliance and tolerability worsen in those
age$ 55 years. Although the ongoing GRAALL-2014 trial also was
designed for patients in the 18 to 59 age range, we planned dose
reductions for all patients age $ 45 years. On the other hand, the
lower age limit to enter GRAALL trials speciﬁcally designed for
elderly patients is now 55 years, with overlap for patients 55 to
59 years of age.
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Table 3. Compliance With the Planned Therapy According to Age (, 55 or $ 55 Years) by Treatment Phase
Treatment Phase
Cumulative
Planned Dose
Patients, No. Patients 18 to 54 Years of Age Patients $ 55 Years of Age
P*
Treatment
Initiated Evaluable No.
Cumulative Dose Actually Received,
Median (IQR) No.
Cumulative Dose Actually Received,
Median (IQR)
First induction 787 738 662 — 76 — —
VCR, mg 8 — 738 662 8 (8-8) 76 8 (8-8) .190
DNR, mg/m2 210 — 738 662 210 (207-210) 76 210 (206-210) .580
L-aspa†, IU/m2 48,000 (30,000) — 737 661 48,000 (36,000-48,000) 76 36,000 (24,000-48,000) , .001
PDN, mg/m2 840 — 736 660 819 (700-840) 76 837 (721-840) .072
Standard-C arm,
mg/m2
1,500 398 370 335 1,500 (1,486-1,500) 35 1,497 (1,477-1,500) .170
Hyper-C arm,
mg/m2
2,550 389 368 327 2,545 (2,488-2,550) 41 2,550 (2,466-2,550) .600
Consolidation 1 691 681 614 — 67 — —
Ara-C, mg/m2 8,000 — 679 613 7,860 (7,600-8,000) 66 7,728 (7,306-8,000) .010
MTX, mg/m2 3,000 — 678 612 2,955 (2,865-3,000) 66 2,874 (2,730-3,000) , .001
CPM, mg/m2 1,000 — 681 614 986 (954-1,000) 67 958 (940-1,000) .005
Consolidation 2 544 474 423 — 51 — —
Ara-C, mg/m2 8,000 — 474 423 7,907 (7,596-8,000) 51 7,643 (7,215-8,000) , .001
MTX, mg/m2 3,000 — 474 423 2,973 (2,856-3,000) 51 2,871 (2,768-3,000) .011
CPM, mg/m2 1,000 — 474 423 995 (956-1,000) 51 970 (938-1,000) .037
Late intensiﬁcation 359 357 315 — 42 — —
VCR, mg 8 — 357 315 8 (8-8) 42 8 (4-8) .051
DNR, mg/m2 150 — 357 315 150 (143-150) 42 147 (140-150) .039
L-aspa, IU/m2 48,000 — 357 315 48,000 (0-48,000) 42 36,000 (0-48,000) .150
PDN, mg/m2 840 — 357 315 809 (688-840) 42 770 (614-826) .028
Standard-C arm,
mg/m2
1,500 179 178 161 1,500 (1,432-1,500) 17 1,470 (1,402-1,500) .092
Hyper-C arm,
mg/m2
2,550 180 179 154 2,507 (2,300-2,550) 25 2,429 (1,620-2,512) .028
Consolidation 3 342 337 297 — 40 — —
Ara-C, mg/m2 8,000 — 337 297 8,000 (7,614-8,000) 40 7,670 (7,403-8,000) .011
MTX, mg/m2 3,000 — 333 295 3,000 (2,880-3,000) 38 2,835 (2,703-3,000) , .001
CPM, mg/m2 1,000 — 334 295 1,000 (964-1,000) 39 958 (940-1,000) .002
NOTE. Compliance with the most important drugs was evaluated at the end of each treatment phase in patients with available data and potentially exposed to the full
planned doses during the treatment phase of interest; patients who died received allogeneic stem-cell transplants in ﬁrst complete remission or experienced relapse
during the treatment phase were not considered in these comparisons.
Abbreviations: Ara-C, cytarabine; CPM, cyclophosphamide; DNR, daunorubicin; hyper-C, hyperfractionated cyclophosphamide; IQR, interquartile range; L-aspa,
L-asparaginase; MTX, methotrexate; PDN, prednisone; standard-C, standard cyclophosphamide; VCR, vincristine.
*Median doses actually received by patients 18 to 54 and $ 55 years of age were compared using the Mann-Whitney U test.
†L-aspa was planned to be administered for a total of eight injections at 6,000 IU/m2 per injection during both ﬁrst induction and late intensiﬁcation phases. In patients
with CNS involvement at diagnosis, the planned number of L-aspa injections was reduced to ﬁve during the ﬁrst induction phase to prevent cumulative toxicities with
early intrathecal therapy; 55 patients had initial CNS involvement, including 51 of the 738 patients evaluable for the ﬁrst induction phase (48 who were 18 to 54 years of
age, three who were $ 55 years of age; P = .35).
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